Bio-business forum at UC Berkeley Nov. 3
31 October 2005
ATTENTION: Biotech, business and venture capital reporters, editors
Mary Ann Godwin, Berkeley Bio-Business Association
A networking dinner for bio-business leaders interested in the unique resources of the University of California, Berkeley, and its Haas School of Business.
Journalists are invited to join more than 150 venture capitalists, entrepreneurs, scientists and industry leaders as they discuss industry trends and opportunities to build relationships across disciplines. Organized by the student-run Berkeley Bio-Business Association, the roundtable will draw experts from the fields of biotech, pharmaceuticals, medical devices, diagnostics and entrepreneurship. The networking reception and dinner will be followed by a panel discussion, "Biotech and Medical Devices: What's Hot/What's Not."
6-10 p.m., Thursday, Nov. 3
San Francisco International Airport Hyatt in Burlingame
Key participants include:
- Frank Fischer, chief executive officer of NeuroPace, Inc. Fischer is former president and CEO of Heartport, Inc., a cardiac surgery company, and former president and CEO of Ventritex, Inc., a company that pioneered implantable cardiac defibrillators.
- David M. Fineman, president, CEO and co-founder of Kinemed and co-founder of SuperGen, Inc.
- Michael Powell, Ph.D., managing director of Sofinnova Ventures. Powell is a former group leader of drug delivery at Genentech and part of the founding team of Cytel.
The "2005 BioEntrepreneurship Roundtable and Venture Capital Forum" was organized by the Berkeley Bio-Business Association at UC Berkeley's Haas School of Business. The student group bridges bio-business interests across the campus and aims to provide a forum for the exchange of ideas and information between the academic community and professionals in biotechnology, pharmaceuticals, medical devices and diagnostics.
The association is hosting the event in partnership with UC Berkeley, with funding provided by grants from the campus and private donations from Fenwick & West LLP, Alta Partners and Rubicor.